This data set includes the estimated number of individuals in Pennsylvania with Drug Use Disorder, which is an approximation for Opioid Use Disorder prevalence. The estimates are developed by applying mortality weights derived from the CDC’s National Center for Health Statistics to statewide illicit drug use estimates from the National Survey on Drug Use and Health (NSDUH, sponsored by the Substance Abuse and Mental Health Services Administration).
This dataset reports the site name, street address, city, county, zip code, telephone number, hours of availability, latitude, and longitude of Pennsylvania prescription drug take-back boxes as of May 2018. These monitored locations include police departments, courthouses, pharmacies, and hospitals/medical centers.
View quarterly trends in buprenorphine dispensation data. Please note that buprenorphine data received by the PDMP is restricted to prescriptions filled by pharmacies. The PDMP does not collect information on the reason a controlled substance is prescribed, nor does it collect data from substance abuse treatment facilities or dispensing prescribers providing buprenorphine for substance abuse treatment. Buprenorphine is sometimes prescribed off-label for pain. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx
This dataset reports the name, street address, city, county, zip code, telephone number, latitude, and longitude of Pennsylvania Department of Drug and Alcohol Programs (DDAP) drug and alcohol treatment facilities in Pennsylvania as of May 2018.
The primary difference between the three types of treatment facilities is their funding. Centers of Excellence (COEs) were grant funded by the Department of Human Services, PacMATs were grant funded by the Department of Health, and all other facilities are funded by either billing insurance or billing the county in the case of uninsured clients.
Programmatically, COEs differ from the other types because they are designed to serve as “health homes” for individuals with Opioid Use Disorder (OUD). This means that the care coordination staff at the COE is charged with coordinating all kinds of health care (physical and behavioral health) as well as recovery support services. They do this by developing hub-and-spoke networks with other healthcare providers and other sources for recovery supports, such as housing, transportation, education and training, etc. All COEs are required to accept Medicaid.
PacMATs also operate in a hub-and-spoke model, but it is different from COEs. PacMATs endeavor to coordinate the provision of Medication Assisted Treatment (MAT) by identifying a core hub of physicians in a health system that work with other providers in the health system (spokes) to train them about the safe and effective provision of MAT so that there are more providers in a health system that are able to confidently prescribe various forms of MAT. I do not know whether all PacMATs are required to accept Medicaid as a term of their receipt of the grant, but I do know that all currently designated PacMATs are health systems that do accept Medicaid. PacMAT services have been advertised as being available to all people regardless of insurance type, so I assume this means they are required to serve Medicaid clients, commercially insured clients, and uninsured clients. In the PacMAT program the Hub is supported right now by grant funding (in the future funding such as a per patient/per month capitated rate) and the spokes bill insurance (both Medicaid and Commercial)
DDAP facilities may also be designated as COEs and/or PacMATs. If they are, it means they applied for a specific grant fund and have committed to carrying out the activities of the grant described above. To be clear, DDAP does not run any treatment facilities; they license them. These can be MAT providers such as methadone clinics, providers of outpatient levels of care (i.e., more traditional drug and alcohol counseling services) or inpatient levels of care, such as residential rehabilitation programs. Every facility is different in terms of the menu of services it provides. Every facility also gets to decide what forms of payment they will accept. Many accept Medicaid, but not all do. Some only accept private commercial insurance. Some accept payment from the county on behalf of uninsured clients. And some charge their clients cash for services.
This dataset contains summary information on opioid drug seizures and arrests made by Pennsylvania State Police (PSP) personnel, stationed statewide, on a quarterly basis. Every effort is made to collect and record all opioid drug seizures and arrests however, the information provided may not represent the totality of all seizures and opioid arrests made by PSP personnel.
Data is currently available from January 1, 2013 through most current data available.
Opioids seized as a result of undercover buys, search warrants, traffic stops and other investigative encounters.
An incident is a Pennsylvania State Police (PSP) recorded violation of the Controlled Substance Act and an entry into the PSP Statistical Narcotics System.
By regulation, entry is made by the PSP as stated in PSP Administrative Regulation 9-6:
When violations of The Controlled Substance, Drug, Device and Cosmetic Act are reported, the required statistical information concerning the incident shall be entered into the Statistical Narcotic Reporting System (SNRS).
Incidents may include undercover buys, search warrants, traffic stops and other investigative encounters
So, an “incident” is not based on any arrest, but on a reported violation, though it often can include arrests.
The incidents that are selected and forwarded to the portal are those that include a record of one or more seizures of the opioid drugs. In turn, a subset of those selected incidents also contains a record of one or more arrests.
This is PSP data only, it would not include any Federal case/incident data.
Statewide number of hospitalizations for opioid overdose categorized by principal diagnosis of heroin or opioid pain medication overdose by year.
This analysis is restricted to Pennsylvania residents age 15 and older who were hospitalized in Pennsylvania general acute care hospitals.
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.
PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.
This dataset reports number of successful naloxone reversals by police officers, as self-reported by municipal police departments, Capitol Police, and Pennsylvania State police. The data is stratified by county and by year. Note that there is no legislation mandating that law enforcement report naloxone reversals to DDAP; these data represent voluntary self-reports from departments.
NA - Not applicable. No FIPS code or county code exist for Pennsylvania State Police and Capitol Police. Also, counties labelled “NA” do not have municipal police departments and are only covered by Pennsylvania State Police.
View quarterly trends in opioid dispensation data for all Schedule II-V opioids.
Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx More information from U.S. Department of Justice
https://www.deadiversion.usdoj.gov/schedules/ Schedule I Controlled Substances
Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy").
Schedule II/IIN Controlled Substances (2/2N)
Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence.
Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone.
Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®).
Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital.
Schedule III/IIIN Controlled Substances (3/3N)
Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®).
Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone.
Schedule IV Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances in Schedule III.
Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).
Schedule V Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.
Countywide counts of newborn hospital stays with Neonatal Abstinence Syndrome (NAS) and countywide rates of newborn hospital stays with (NAS) per 1,000 newborn stays. Neonatal Abstinence Syndrome, or neonatal drug withdrawal, is an array of problems that develops shortly after birth in newborns who were exposed to addictive drugs, most often opioids, while in the mother’s womb. Withdrawal signs develop because these newborns are no longer exposed to the drug for which they have become physically dependent. This analysis is restricted to newborns with Pennsylvania-state residence who were hospitalized in Pennsylvania hospitals.
Disclaimer: Pennsylvania Health Care Cost Containment Council (PHC4) database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers. PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.